Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2024-08-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物第二届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the supervisory board meeting resolutions of Maiwei (Shanghai) Biotech Co., Ltd. It includes the approval of the company's 2024 semi-annual report and a special report on the use of raised funds. The document states that the actual reports are disclosed on the Shanghai Stock Exchange website and media, indicating this document itself is not the full semi-annual report but an announcement of the meeting resolutions and approvals related to those reports. The document length is short (1083 characters), and it primarily serves as a meeting resolution announcement rather than containing substantive financial data or the full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution disclosure rather than the Interim/Quarterly Report (IR) itself or a Report Publication Announcement (RPA) since it contains meeting resolution details rather than just a report release notice.
2024-08-30 Chinese
迈威生物2024年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2024 Third Extraordinary General Meeting of Shareholders" of Maiwei (Shanghai) Biotechnology Co., Ltd. It includes meeting instructions, agenda, and a specific proposal regarding increasing credit and financing limits for 2024. The content is focused on the meeting procedures, voting rights, and agenda items for the shareholders' meeting. The document length is 3514 characters, which is relatively short and consistent with meeting materials rather than a full report. There is no detailed financial data or comprehensive financial statements present. The document is clearly a set of meeting materials prepared for a shareholders' meeting, not the announcement of voting results or a proxy solicitation. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual or Extraordinary General Meeting.
2024-08-30 Chinese
迈威生物2024年度”提质增效重回报”行动方案
Management Reports Classification · 95% confidence The document is a detailed action plan for the year 2024 by 迈威（上海）生物科技股份有限公司, focusing on innovation drug R&D, commercialization, global business expansion, production capacity, corporate governance, investor communication, and management incentives. It contains extensive operational, strategic, and business development information but does not include financial statements or quarterly/yearly financial results. It is not a regulatory announcement, certification, or voting result. The document is comprehensive and forward-looking, resembling a management report explaining business trends, strategies, and outlook rather than a formal annual or interim financial report. Therefore, the best fitting category is Management Reports (MDA).
2024-08-30 Chinese
迈威生物2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, risk factors, company overview, accounting data, and financial indicators for the first half of 2024 (January to June). The document is comprehensive, with a length of 15,000 characters, and includes actual financial statements and substantive financial analysis. It is explicitly stated as a half-year report and is unaudited. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR).
2024-08-30 Chinese
迈威生物自愿披露关于9MW2821联合PD-1单抗一线治疗尿路上皮癌的Ⅲ期临床研究获得CDE同意的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about the approval by the CDE (Center for Drug Evaluation) of a clinical trial protocol for a Phase III clinical study of a drug (9MW2821) for urothelial carcinoma. It provides detailed information about the drug, its clinical trial status, regulatory designations, and risk warnings. The document is a voluntary disclosure announcement about clinical research progress and regulatory approval for the trial protocol. It does not contain financial data, earnings, management changes, or other typical financial report content. It is not a report itself but an announcement of regulatory and clinical trial progress. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-08-25 Chinese
迈威生物自愿披露关于9MW2821治疗宫颈癌的Ⅲ期临床研究获得CDE同意的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a company about receiving approval from the CDE (Center for Drug Evaluation, China) to start a Phase III clinical trial for a drug treating cervical cancer. It contains detailed information about the drug, clinical trial phases, regulatory approvals, and risk warnings. The document is an announcement of a regulatory or clinical development milestone rather than a financial report, earnings release, or management discussion. It does not contain financial statements or data. It is not a report publication announcement since it is a substantive announcement itself. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about clinical trial approval and related information that does not fit other specific categories.
2024-08-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.